HysensBio is a peptide biotechnology company focused on developing innovative therapeutics for dental diseases such as dentin hypersensitivity, dental caries, and periodontal diseases. Its novel regenerative technology is based on cell reactivation. The company developed a new peptide derived from CPNE7 protein that activates various dental cells to restore physiological dentin, periodontal ligament, and cementum. The peptide showed promising results in phase 1/2a clinical study. HysensBio is providing a solution to common, lifetime dental problems using regenerative technology, ultimately helping people extend the longevity of their natural teeth. The peptide is a novel, 10-amino acid peptide that activates various dental cells to promote regeneration. In the case of dentin hypersensitivity, it penetrates into the exposed dentinal tubules and activates the odontoblast to promote physiological dentin formation. The regenerated dentin occludes the tubules, blocking out various painful stimuli. This mechanism of action differentiates HysensBio's technology from other players in the market as it permanently blocks our painful stimuli by regenerating physiological dentin rather than temporarily blocking the surface or numbing the nerves. For periodontal diseases, the peptide activates periodontal ligament fibroblasts which promotes well-aligned periodontal ligament and cementum formation, ultimately resulting in periodontal regeneration. CPNE7 is expressed and functions in ectoderm- and neural crest- derived cells. As the novel peptide reacts differently depending on the cell types and their niche, in addition to dental indications, the novel technology can be used for various indications such as dermatological and retinal indications, which were deemed incurable in the past.